What to know about anti-aging medication in development that could help dogs live longer

The development of LOY-001, a drug designed to potentially extend the lifespan of dogs, particularly large breeds, is generating excitement among pet owners and veterinarians. Here's what you need to know:

Is the drug designed for all dogs?

• LOY-001 targets large adult dogs specifically. Larger breeds tend to have shorter lifespans compared to smaller breeds, and this medication aims to address that disparity.

How does the drug work?

• The medication works by interacting with insulin growth factor-1 (IGF-1), a hormone associated with growth and aging acceleration in dogs. Lower insulin levels in dogs have been linked to reduced frailty and a higher quality of life. Since IGF-1 levels are naturally higher in large dogs, they typically do not live as long as smaller dogs.

Is the drug a pill?

• No, LOY-001 is a long-acting injectable medication. It is administered by a veterinarian every three to six months.

Are there any side effects for dogs?

• Preliminary studies indicate that the drug can cause mild and temporary gastrointestinal distress in dogs as a side effect.

Why is the medication not yet available?

• More research and clinical trials are required before the U.S. Food and Drug Administration (FDA) can approve LOY-001 for use. Loyal, the company behind the drug, has received signals from the FDA that the data so far shows potential effectiveness, but full approval will depend on the outcomes of a large clinical trial and a thorough review of safety and manufacturing data. Loyal aims for conditional FDA approval by 2026.

This innovative approach to canine aging could revolutionize how we manage the health and longevity of our furry friends, especially those of larger breeds. As research progresses, the veterinary community and pet owners alike are hopeful for a future where "dog years" could mean longer, healthier lives for dogs.